Dapagliflozin for improving blood flow in septic shock
Part of Infections clinical trials.
This study tests whether a medication called dapagliflozin (normally used for diabetes and heart failure) can help improve blood flow in small vessels (microcirculation) for people in septic shock, a life-threatening condition caused by severe infection. If the medication works, it may help restore normal blood flow and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be in the intensive care unit (ICU) with septic shock diagnosed within the last 12 hours.
- You must have signs of poor blood flow in small blood vessels, like blotchy skin (mottling) or slow nail-bed refill.
- You cannot be already taking an SGLT2 inhibitor (like dapagliflozin) for diabetes or heart failure.
- You cannot have type 1 diabetes, diabetic ketoacidosis, or be on dialysis for kidney failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether empagliflozin, a diabetes medicine, helps improve blood flow in tiny blood vessels for people in cardiogenic shock. If it helps, it could improve recovery for people with this serious heart condition.
This trial studies whether starting empagliflozin early in adults with cardiogenic shock helps people live longer and have fewer hospital returns, while also checking heart pumping and kidney function. It may help some ICU patients, but eligibility is strict and depends on kidney function and prior medication use.
This study tests whether a medicine called dapagliflozin can help reduce inflammation in people with sepsis (a serious blood infection that can cause organ failure). It focuses on a protein in the blood that controls inflammation and might improve recovery.
This trial tests whether a type of diabetes medicine (SGLT2 inhibitors) can help adults with sepsis, a life-threatening response to infection. If you have new-onset sepsis and can take oral medicine, you may be eligible.
This study tests whether a medicine called dapagliflozin can improve heart function in people hospitalized with acute heart failure. It may help the heart pump more efficiently and improve recovery.
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
Hear when a new Septic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.